Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health presented data at ESPGHAN 2026 demonstrating that its drug crofelemer significantly reduced parenteral support requirements in pediatric intestinal failure patients. Results showed a reduction of up to 48% in normalized weekly parenteral support for one MVID patient and up to 40% for two SBS patients after more than 12 months of therapy.
Key figures
- Drug Name
- Crofelemer
- Guidance
- Planned filing of an NDA for the indication of MVID in mid-2027
- Therapy duration months
- >12
- Ps reduction sbs percent
- 40
- Ps reduction mvid percent
- 48
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.